IGHE and asthma: Therefore, dupilumab is the first biologic approved and specifically indicated for the treatment of uncontrolled severe asthma with Type 2 inflammation: asthma that includes allergic (anti-IgE) and/or eosinophilic (anti-IL5) phenotypes.